BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Grannus BioSciences Limited 

Cids Thomson Building, Room 203
University Avenue
Glasgow  Scotland  G2 2LD  United Kingdom
Phone: 01-41-330-2564 (UK) or 949-361-6941 (US) Fax:


SEARCH JOBS

Grannus BioSciences Limited (GBL) is discovering and developing breakthrough bio-pharmaceuticals to combat inflammatory and hyperproliferative disorders. GBL’s efforts are focused on finding biologic and small molecule drugs that have the appropriate anti-inflammatory or anti-proliferative properties to regulate aberrant processes in the dermis, respiratory or gastrointestinal tract. The company has several lead clinical stage products in development. The first is a phase II small molecule pharmaceutical with application to the pre-malignant hyperproliferative condition known as Actinic Keratosis. The second is a Phase I biologic, thymosin beta 4 sulfoxide, which is a potent inhibitor of neutrophils that is formulated for dermatologic applications. Grannus has a pipeline of preclinical molecules that are also being developed for additional inflammatory applications.

Grannus seeks strategic alliances and partnerships that will support the global commercialization of its products. The Company plans to out-license rights to its product opportunities at Phase I or II to a partner in the major territories (North America, Europe, or Japan), while retaining rights in the rest of the world. Grannus also is looking to in-license additional products for development.

Last Updated: 12-12-05

 Key Statistics


Email: ir@grannusbiosciences.com
Ownership: Private

Web Site: Grannus BioSciences Limited
Employees:
Symbol: 
 









 Company News
Grannus BioSciences Limited Announces Appointment Of EGeen As CRO 12/13/2005 3:37:42 PM    More...
Grannus BioSciences Limited Announces Agreement For Clinical And Preclinical Molecules 10/21/2005 6:41:05 PM    More...

//-->